EHA 2022 | Highlights in AML: quizartinib in elderly patients & in frontline FLT3-mutated AML
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares his thoughts on the most interesting abstracts in acute myeloid leukemia (AML) that will be shared at the EHA meeting, including data on the QuANTUM-First (NCT02668653) study, and data on a study evaluating the combination of decitabine, venetoclax and quizartinib in elderly patients with AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier; Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron; Speaker’s Bureau: Cure, Hikma; Honoraria: Genzyme
